Zymeworks to open new EU HQ in Dublin, Ireland
Canadian biotech company Zymeworks has announced plans to open its new Clinical and Regulatory EU headquarters in Dublin, Ireland.
Zymework focuses on developing therapeutics for difficult-to-treat cancers and other serious diseases. The new Clinical and Regulatory HQ will allow Zymeworks to coordinate clinical trials in the EU and progress early-stage clinical programmes.
New roles within the HQ will include regulatory affairs, clinical operations, clinical data management and support functions, creating up to 20 jobs.
Kenneth Galbraith, chair and CEO of Zymeworks, commented: “[The company is at] an exciting stage of global expansion with a portfolio of antibody-drug conjugates and multi-specific antibody therapeutics in clinical trials and preclinical development. We are excited to announce our establishment in Dublin, which will provide us with the opportunity to engage with European cancer researchers and investigators, and recruit a larger proportion of patients in clinical studies planned in the EU during the global drug development process.”
Michael Lohan, DA Ireland’s CEO, said: “Zymeworks joins a growing cluster of biopharmaceutical companies establishing corporate and technical management operations in Ireland. Zymeworks is the first Canadian biopharmaceutical company to establish an international headquarters in Ireland and IDA Ireland is committed to winning more investment from the region. We welcome the company’s plans to create high-value career opportunities and we look forward to continuing to work closely with Zymeworks.”
AstraZeneca’s new headquarters in Cambridge, United Kingdom are expected to cost more than double the …
Jazz Pharmaceuticals has announced its intention to expand its staff numbers at two of its …